# Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

> **NCT07090161** · PHASE2 · RECRUITING · sponsor: **Vanda Pharmaceuticals** · enrollment: 240 (estimated)

## Conditions studied

- Hypertension
- Uncontrolled Hypertension

## Interventions

- **DRUG:** iloperidone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07090161
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-15
- **Primary completion:** 2026-10
- **Final completion:** 2026-11
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2026-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07090161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07090161, "Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT07090161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*